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In order to characterize the biological properties of human immunodeficiency virus type 1 (HIV-1) variants
from different tissues (peripheral blood mononuclear cells [PBMC], lymph node, spleen, brain, and lung) of
one patient, we have chosen long-range PCR to amplify virtually full-length HIV proviruses and to construct
replication-competent viruses by adding a patient-specific 5* long terminal repeat. To avoid selection during
propagation in CD41 target cells, we transfected 293 cells and used the supernatants from these cells as
challenge viruses for tropism studies after titration on human PBMC. Despite differences in the V3 loop of the
major variants found in brain and lung compared to lymphoid tissues all recombinant HIV clones obtained
showed identical cell tropism and replicative kinetics. After infection of human PBMC these viruses replicated
with similar kinetics, with a slow/low-titer, non-syncytium-inducing phenotype. In contrast to the prediction of
macrophage tropism, drawn from the V3 loop sequence, none of these viruses infected monocyte-derived
macrophages. The challenge of blood dendritic cells by these recombinant viruses in the presence of tumor
necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and interleukin-4 resulted in a
productive infection only after adding stimulated CD41 T lymphocytes. Therefore, the biological properties of
the HIV-1 variants derived from nonlymphoid tissue of this patient did not differ from those of HIV-1 variants
from lymphoid tissue with respect to tropism for primary cells such as PBMC, macrophages, and blood
dendritic cells.
The coexistence of natural variants of genetically distinct
human immunodeficiency virus type 1 (HIV-1) within individ-
uals has been clearly demonstrated (2, 16, 26, 39, 49). Isolates
of HIV-1 derived from peripheral blood mononuclear cells
(PBMC) are highly variable over time and show changes in the
biological phenotype during the course of infection (15). It has
been demonstrated that early in infection HIV-1 isolates show
a slow/low-titer, non-syncytium-inducing (NSI) phenotype and
preferentially infect monocyte-derived macrophages (MDM)
and PBMC. With the onset of AIDS, most but not all patients
harbor rapid/high-titer viruses, often with a syncytium-inducing
(SI) phenotype, which infect T-cell lines efficiently but may
have a reduced ability to infect MDM (1, 52–54).
Studies of HIV-1 variants from tissues other than PBMC
suggest they harbor distinct variant populations compared to
PBMC. Viruses from the central nervous system are geneti-
cally and phenotypically different from viruses in the blood or
spleen (10, 23, 45). Some neurological HIV-1 variants infect
microglial cells and brain capillary endothelial cells (40, 47),
whereas HIV variants recovered from the bowel show differ-
ences in induction of cytopathology and sensitivity to neutral-
ization compared to blood isolates (3).
Until recently, there has been no systematic attempt to
quantify and characterize HIV-1 variants throughout the body
at different disease stages. Donaldson et al. (20, 21) demon-
strated large amounts of HIV provirus in nonlymphoid tissues
(brain, lung, colon, and kidney) in AIDS patients, whereas
patients who died in the asymptomatic phase did not have
consistently detectable provirus in these tissues. The analysis of
the V3 loop sequence derived from AIDS patients revealed
differences between HIV variants from lymphoid tissues and
nonlymphoid tissues (21).
To investigate whether these sequence differences reflected
variation in the phenotype of HIV-1 in different tissues, we
employed the long-range PCR technique to construct full-
length proviruses derived from lymphoid tissue (PBMC, lymph
node, and spleen) and nonlymphoid tissue (brain and lung)
and compared the biological properties of the molecular
clones containing the major V3 loop variants found in these
tissues with respect to tropism for primary cells such as PBMC,
MDM, and blood dendritic cells (BDC).
To our knowledge, this is the first time that replication-
competent viruses have been constructed by long-range PCR
amplification of genomic DNA prepared directly from differ-
ent tissues. Although the sensitivity has to be improved to
avoid potential recombination events occurring during the am-
plification steps (61), the approach described here allows the
recovery of full-length infectious molecular clones without pas-
saging on donor PBMC and can provide tissue-specific refer-
ence clones with respect to the genotype and phenotype
present in vivo.
MATERIALS AND METHODS
Patient samples. DNA samples used for PCR amplification were derived from
various tissues from an AIDS patient by autopsy. Patient 4 (20) died 5 years after
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infection with HIV-1 and was chosen because of the relative high provirus load
in the lymphoid as well as the nonlymphoid tissue, as shown previously (21).
Samples of brain (left frontal lobe), lung, mesenteric lymph node, and spleen
tissues from patient 4 were dissected into 1- to 2-cm pieces and stored at 270°C.
DNA was extracted from these tissues and whole blood to obtain total DNA as
previously described (49).
Long-range PCR and construction of a full-length provirus clone. In order to
construct a full-length provirus, we used a primer pair designed to amplify 9.0 kb
covering the primer binding site up to the 39 end of the 39 long terminal repeat
(LTR) (U5 region). The nucleotide sequences of the primers and the position of
the 59 base in the HXB2 provirus (41) were 626(1), 59 AGGGGGCCAAGTC
GGCCTCTCTAGCAGTGGCGCCCGAACAGGG 39, and 9690(2), 59 AGTC
GCGGCCGCGGTCTGAGGGATCTCTAGTTACCAGAGTC 39. The under-
lined sequences mark the recognition sites for the restriction enzymes SfiI, NarI,
and NotI, respectively, to facilitate the cloning of the 9.0-kb fragment into
pGEM13-LTR (see below). The long-range PCRs were performed with a mix-
ture of AmpliTaq (Perkin-Elmer Cetus) and Pfu polymerase (Stratagene) in an
8:1 ratio. Between 100 and 500 ng of genomic DNA derived from whole blood
from patient 4 were sufficient to obtain a 9.0-kb amplification product in a 100-ml
reaction mixture containing 200 mM Tris-HCl (pH 8.7), 100 mM KCl, 20 mM
MgSO4, 100 mM (NH4)2SO4, 1 mg of bovine serum albumin/ml, 250 mM (each)
deoxynucleoside triphosphate, and 2 pmol of each primer. All reactions were run
on an Omnigene Thermal Cycler (40 cycles of 96°C for 30 s, 60°C for 30 s, and
68°C for 10 min).
To construct a full-length provirus, we amplified in a separate PCR a 59 LTR
with the primer pair 56(1) (59 GCAGGACGTCAAGCTTCACACACAAGGG
TACTTGCCTCATTGGCAG 39) and 651(2) (59 GAAGGGCCGACTTGGC
CCCCTGTTCGGGCGCCACTGCTAGAAG 39). The underlined sequences
mark the recognition sites for the restriction enzymes HindIII, SfiI, and NarI,
respectively. The resulting 0.6-kb product was digested with HindIII and SfiI and
cloned into pGEM13 to obtain pGEM13-LTR. All 9.0-kb PCR products were
cloned into this vector by using the restriction enzymes NarI (primer binding site)
and NotI (39 LTR).
Construction of recombinant proviruses. A nested primer pair to amplify the
39 half of the proviral genome was also designed. Modifying primers described by
Kusumi et al. (32) in length and restriction enzyme recognition sites, we ampli-
fied 4.5 kb with genomic DNA from all tissues obtained (brain, lung, lymph node,
and spleen). The outer primer pair was 4955(1) (59 TAGTAGACGTCTGGA
AAGGTGAAGGGGCAGTAGTA 39; AatII recognition site underlined) and
9690(2). The second, nested PCR was performed with the primer pair 5048(1)
(59 TGTGTGACGTCACAGATGGCAGGTGATGATTGTGT 39) (AatII rec-
ognition site underlined) and 9624(2) (59 TAAGGCGGCCGCGGCAAGCTT
TATTGAGGCTTAG 39; NotI recognition site underlined) (40 cycles of 96°C for
30 s, 55°C for 30 s, and 68°C for 6 min were run for each primer pair). The
resulting products were cloned into pGEM5 with the restriction enzymes indi-
cated, and the V3 sequence (in parentheses) was determined by using the ABI
sequencing kit and primer V3f1 (59 TGGCAGTCTAGCAGAAGAAG 39).
The sequencing of the central region of the 39 halves obtained revealed a single
EcoRI site at position 5745, 85 nucleotides 59 of the tat open reading frame. This
EcoRI site was used together with the NotI site introduced by the inner antisense
primer 9624(2) to exchange the 39 half of a PBMC-derived full-length clone with
the 39 halves obtained from brain, lung, lymph node, and spleen (see Fig. 2).
Sensitivity and fidelity of the long-range PCR approach. To estimate the
sensitivity of the 9.0-kb long-range PCR and the 4.5-kb nested long-range PCR
we extracted genomic DNA from human PBMC spiked with different amounts of
ACH2 cells (these cells carry a single copy of HIVIIIB per genome). The final
concentration of proviruses per 200 ng of genomic DNA for each mixture was
calculated and used in the PCR as a target. The fidelity of this prolonged PCR
approach was checked by digesting the 9.0- and 4.5-kb fragments which were
PCR products obtained by using HXB2-containing plasmid as a target. Digestion
with 17 selected restriction enzymes, divided throughout the proviral genome,
revealed no mutation at least in the restriction enzyme recognition sequences
(data not shown).
Transfection of recombinant HIV clones and titration on PBMC. The human
kidney cell line 293 was transfected with Lipofectamine (GIBCO) according to
the manufacturer’s protocol, and virus in the cell culture supernatant was har-
vested 4 days later. After DNase I (Promega) treatment to digest remaining
plasmid DNA and chromosomal proviral DNA from dead cells, the amount of
p24gag was assessed by using an in-house p24gag enzyme-linked immunosorbent
assay (ELISA) as described earlier (13). The 50% tissue culture infectious dose
(TCID50) was determined by using stimulated human PBMC as target cells and
serial diluted virus in quadruplicate (37).
Primary cells. PBMC from HIV-seronegative individuals were purified by the
Ficoll-Hypaque method, stimulated with 0.5 mg of phytohemagglutinin A (PHA;
Sigma)/ml for 48 h, and maintained in RPMI 1640 with 20% fetal calf serum
(FCS), 20 U of recombinant interleukin-2 (IL-2; Boehringer Mannheim)/ml, and
100 U of both penicillin and streptomycin/ml.
MDM were purified by adherence and cultured as described by Gregory et al.
(28). Briefly, 2 3 107 freshly isolated PBMC were added to 140-mm-diameter
bacterial dishes and incubated at 37°C for 2 h. Nonadherent cells were washed off
by vigorous pipetting, and the remaining cells were cultured for 4 days in RPMI
1640–5% FCS–10% heat-inactivated human serum. The macrophages were
scraped off, counted, and set up in 24-well plates (5 3 105 cells per well) or
96-well plates (104 cells per well), and the next day they were challenged with the
recombinant viruses.
BDC were obtained from freshly isolated PBMC after overnight culture in
RPMI 1640–10% FCS. The next day, the nonadherent cells were separated from
T lymphocytes by centrifugation over 13.7% (wt/wt) metrizamide. These prepa-
rations were either negatively selected for dendritic cells by depletion of CD31
T lymphocytes, CD141 monocytes/macrophages, and CD191 B lymphocytes by
using the Mini-Macs system (Milteny-Biotec) or positively selected after incu-
bation with the monoclonal antibody HB15a (62), a specific marker for dendritic
cells, followed by a second incubation with a bead-conjugated rat anti-mouse
immunoglobulin G2a antibody (Milteny-Biotec). Both protocols resulted rou-
tinely in a cell population containing less than 1% T and B lymphocytes and
monocytes as determined by fluorescence-activated cell sorter analysis. The
remaining cells (.98%) were BDC as determined by appearance. BDC (105)
were challenged with recombinant virus and cultured in RPMI 1640–10% FCS
containing 100 U of tumor necrosis factor alpha, 800 U of granulocyte-macro-
phage colony-stimulating factor, and 500 U of IL-4 per ml. After overnight
incubation, the cells were washed four times, and stimulated T cells (105 cells per
well) were added to half of the wells.
Immunostaining of HIV-infected cells. The immunostaining method was sim-
ilar to that described by Chesebro and Wehrly (11), adapted for a b-galactosidase
conjugate as described earlier (14).
Detection of late reverse transcriptase products after infection. Forty-eight
hours after challenge, cells were lysed and DNA was extracted by using the
Nucleon DNA preparation kit (Scotlabs) according to the manufacturer’s pro-
tocol. The entry PCRs were performed with 0.2 mg of genomic DNA per 50-ml
reaction mixture containing 66 mM Tris-HCl (pH 8.8), 4 mM MgCl2, 16 mM
(NH4)2SO4, 200 mM (each) deoxynucleoside triphosphate, and 5 pmol of each
primer. The expected 175-bp fragment was obtained only after two strand
switches had occurred during the reverse transcription (positive primer R region,
59 CTAACTAGGGAACCCACTG 39 [nucleotides 498 to 516], and the minus
strand primer gag region, 59 TCCTGCGTCGAGAGAGCTC 39 [nucleotides 693
to 675] [35 cycles of 96°C for 30 s, 65°C for 30 s, and 72°C for 45 s were used] (33).
The sensitivity of the entry PCR was determined by using HIV-1GUN-1wt (titrated
on MDM) to infect MDM with multiplicities of infection of 1.0, 0.1, 0.01, and
0.001. The lowest level of input virus detected was approximately 40 infectious
units. To verify the standardization of the input DNA, control reactions with
primers amplifying a product from the glyceraldehyde-3-phosphate dehydroge-
nase gene were used. The reactions were performed under the same conditions
as for the entry PCR by using the 59 primer 59 TGGATATTGTTGCCATCAA
TGACC 39 and the 39 primer 59 GATGGCATGGACTGTGGTCATG 39 for 20
cycles of 96°C for 30 s, 60°C for 30 s, and 72°C for 30 s (33).
Single-round virus infectivity assay. env genes from selected tissue-derived
proviral 39 halves (E4, LN15, S8, B8, and L5) were cloned into plasmid pSVIII-
env (30) under the control of an HIV-1 LTR promoter. This was done by
digesting the tissue-derived 39-half proviral genomes with KpnI and XhoI and
replacing the HXB2 env coding region in pSVIII after (partial) digestion with
KpnI and XhoI.
Cos-1 cells (2 3 105 cells per well) were cotransfected with 5 mg of either
pSVIII-E4, pSVIII-LN15, pSVIII-S8, pSVIII-B8, or pSVIII-L5 and 2.5 mg of
HXBDenvCAT, an env-deficient HIV-1 provirus which contains a chloramphen-
icol acetyltransferase (CAT) gene in place of the nef gene, by using Lipo-
fectamine. Three days after transfection supernatant was collected, and equiva-
lent amounts of produced virions (10 ng of p24gag) were used to infect CCC/CD4
cells transiently expressing the chemokine receptors CXCR4, CCR5, and CCR3
(50). After two days the cells were lysed and the amount of CAT in the lysate was
determined by using a CAT-ELISA (Boehringer Mannheim) according to the
manufacturer’s protocol. Two different virus stocks were used in at least three
different challenge experiments.
RESULTS
Sensitivity of the long-range PCR approach and construc-
tion of PBMC-derived full-length HIV-1 clones. The long-
range PCR performed with different amounts of proviruses per
given DNA concentration revealed successful amplification of
the 9.0-kb fragment when at least 4 3 103 proviruses were
present in the reaction. The number of proviruses necessary
could not be reduced by employing a second round (Fig. 1). By
using the primer pairs to amplify only the 39 half of the proviral
genome, a much higher sensitivity was obtained. The nested
PCR approach yielded a 4.5-kb fragment when only 20 provi-
ruses were present in the reaction. This high sensitivity allowed
the amplification of 39-half viral genomes from genomic DNA
prepared from lymph node, spleen, brain, and lung tissue col-
lected postmortem from patient 4 (21). Because of the high
proviral concentration in PBMC from this patient, we were
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able to amplify a 9.0-kb fragment by using 200 ng of genomic
DNA. This fragment was cloned into pGEM13-LTR. The se-
quencing of the V3 loop revealed exactly the same V3 loop
amino acid sequences as published previously (21) (Fig. 2).
Two of 12 full-length HIV clones derived from PBMC DNA
replicated after infection of donor PBMC (data not shown).
It is possible that recombinant genomes are generated dur-
ing PCR amplification. This could occur if an unfinished strand
annealed to a different parental sequence. The strand would
then be completed with the second sequence as template. To
assess such recombination during the PCR process for the
4.5-kb fragments, we performed long-range PCR using two
different provirus-containing plasmids (pHXB2 and pGUN-
1wt) at equal target numbers (102 targets). After cloning the
PCR products, a restriction analysis and partial sequencing
revealed that four of 11 (36%) 4.5-kb clones contained recom-
binants between pHXB2 and pGUN-1wt. (Cloned fragments
with 39 sequences characteristic of one infectious clone and 59
sequences characteristic of the other were considered to be
recombinants.)
Construction of recombinant HIV clones with tissue-specific
3* halves. In contrast to PBMC (see above) the proviral load in
other tissues was relatively low. Because of the low sensitivity
of the 9.0-kb long-range PCR, we decided to amplify only
proviral 39 halves and to construct recombinant viruses with
the PBMC-derived full-length infectious clone as a backbone.
Restriction enzyme analysis revealed a single EcoRI site in all
amplified 4.5-kb fragments 85 nucleotides upstream of the tat
open reading frame. We constructed 20 full-length clones con-
taining 39 halves derived from different tissues as follows: 7
from lymph node, 5 from spleen, 5 from brain, and 3 from lung.
Each of these clones showed exactly the same V3 loop se-
quence described by Donaldson et al. (21) for the major vari-
ants found in these different tissues. The major V3 loop se-
quence from lymphoid tissue (PBMC, lymph node, and spleen)
differs in six amino acids from the major sequence found in
nonlymphoid tissue (brain and lung). Figure 2 shows only those
virus clones that were replication competent in PBMC. These
recombinant HIV clones were transfected in 293 cells, and the
harvested virus was used for titration on donor PBMC and for
all challenge experiments. To investigate the possibility that
inhibitory sequences in the 59 half of the PBMC-derived HIV
clone HIVE4 might interfere with tropism for macrophages (4,
29, 57), we constructed two recombinant viruses carrying the 39
halves of HIVGUNwt, a dual-tropic HIV clone infecting T-cell
lines and macrophages (38), and the 39 half of HIVSF162, a
monocytotropic HIV clone (10), by using long-range PCR and
the same cloning strategy as described for the patient 4 tissue-
specific recombinant viruses. These recombinant viruses were
transfected into 293 cells and titrated the same way.
Replication kinetics of recombinant viruses after infection
of PBMC. After titration of all recombinant HIV clones, 106
PBMC were infected with 104 TCID, and the replication ki-
netics were monitored by using a p24gag ELISA (HIV-1 p24
core profile ELISA; Du Pont) over the following 28 days. As
shown in Fig. 3, all viruses showed a peak in p24gag production
in the culture supernatants after approximately 10 days. No
virus-induced syncytia in these cultures or in CD41 T-cell lines
(C8166, Molt4, and MT-2) were observed. Therefore, all vi-
ruses showed a NSI phenotype. The amount of p24gag in the
culture supernatants after infection with the recombinant
clones was about 10 times less than in the culture supernatants
infected with the laboratory-adapted, SI HIV-1 strains
HIVHXB2 and HIVGUNwt (data not shown). The replication
kinetics did not reveal a clear difference between recombinant
viruses derived from lymphoid tissue and those derived from
nonlymphoid tissue (Fig. 3).
Tropism studies with MDM and BDC. Because of the close
resemblance of the V3 loop sequences of all recombinant HIV
clones with the consensus sequence for primary lymphocyte
and macrophage-tropic viruses (34), we expected productive
infection of MDM and BDC by these viruses. The infection
experiments were performed by using 5 3 105 infectious units
of each recombinant virus (assessed on PBMC) plated onto
5 3 105 MDM and BDC (multiplicity of infection 5 1), re-
spectively. The MDM cultures were maintained over 21 days,
and supernatants collected on days 7, 14, and 21 did not con-
tain detectable levels of p24gag (HIV-1 p24 core profile ELISA;
detection limit, 12.5 pg/ml). After 21 days PHA-stimulated
PBMC were added to the cultured MDM in order to amplify a
low-level HIV-1 replication. But this virus rescue assay as well
as an immunostaining for p24gag on MDM 21 days after infec-
tion did not reveal any replication of HIV-1 in these cultures
(Table 1). The control viruses (E4/GUNwt and E4/SF162)
were successfully rescued even after an infection at a multi-
plicity of infection of 0.01. This result was confirmed by the
failure to amplify late reverse transcription products in lysates
of macrophages prepared 48 h after challenge (data not
shown). The detection of p24gag in culture supernatants after
challenge with the recombinant viruses E4/GUNwt and E4/
SF162 (Fig. 2) clearly indicates the absence of inhibitory se-
quences in the 59 half of the PBMC-derived provirus, such as
mutations in the basic domain of p17gag (4). The sequences of
the chimeric vpr genes obtained due to the recombination at
the EcoRI site do not differ from those of the wild-type vpr and
do not encode premature stop codons (29, 57). Although the
recombinant viruses derived from patient 4 contain V3 loop
amino acid sequences that predict a macrophage-tropic virus,
none of them could infect macrophages.
After challenge of 5 3 105 BDC with the recombinant vi-
ruses (5 3 105 TCID50), we did not detect p24
gag in the cell
supernatants up to 20 days, nor could we see immunostained
cells after fixation (Table 1). However, if stimulated autolo-
gous T cells were added one day after challenge, p24gag was
detected as early as 5 days after infection. Using CD191 pri-
mary B cells instead of BDC, we did not detect p24gag after the
coculture with autologous T cells (data not shown). Therefore,
FIG. 1. (Top) Location of primers used in this study. The primers amplified
either the 59 LTR, the 9.0-kb amplicon, or the 4.5-kb amplicon. Arrowheads
indicate the direction of transcription. (Bottom) Titration of sensitivity of PCR
primers. Genomic DNA was prepared from ACH2 cells mixed with human
PBMC. The PCR products were resolved by electrophoresis through 0.6% aga-
rose gels and visualized by using ethidium bromide.
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BDC were able to pass virus to T cells in the coculture system,
but they do not support a productive infection with HIV-1 on
their own. The replication kinetics in this BDC–T-cell cocul-
ture system did not show any difference between molecular
clones derived from lymphoid tissue (PBMC, lymph node, and
spleen) and molecular clones derived from nonlymphoid tis-
sues (brain and lung).
Coreceptor use of tissue-derived envelope glycoproteins. To
assess the efficiency with which the tissue-derived envelope
glycoproteins mediate early events of HIV-1 infection, an env
complementation assay (30) was utilized. Pseudotype HIV-1
viruses were produced by cotransfection of COS-1 cells with
two plasmids, pHXB2DenvCAT and pSVIII. Different pSVIII
plasmids encoding the envelope glycoproteins derived from
selected tissue-derived clones, E4 (PBMC), LN15 (lymph
node), S8 (spleen), B8 (brain), and L5 (lung), and two control
viruses, GUN-1wt (dual tropic) and HXB2 (T-cell line tropic),
were used. An equal amount of p24gag-containing supernatant
was incubated with CCC/CD4 cells transiently expressing the
chemokine receptors CCR3, CCR5, and CXCR4. A CAT-
ELISA performed 3 days after the infection of the target cells
revealed that all tissue-derived envelope glycoproteins are able
to utilize the chemokine receptors CCR3 and CCR5 but not
CXCR4 (Fig. 4). The usage of CCR3 and CCR5 correlates
with the finding that all recombinant viruses are of the NSI
phenotype but does not explain the lack of macrophage tro-
pism. The use of U87/CD4 cells stably expressing the chemo-
kine receptors CCR3, CCR5, and CXCR4 (kindly provided by
D. Littman) and the recombinant viruses confirmed the find-
ings of the env complementation assay (data not shown).
DISCUSSION
Construction of replication-competent HIV clones by using
long-range PCR. In order to construct replication-competent
HIV clones representing the genotype present at a specific
time point in a specific tissue we used long-range PCR. This
approach allowed us to construct full-length proviruses con-
taining the major V3 loop sequence found in PBMC of patient
4. The procedure led to successful amplifications provided at
least 4 3 103 proviruses were present in the reaction. This
limited sensitivity could result in the amplification of recom-
binant proviruses generated during PCR (7, 46, 61). However,
the low recovery of replication-competent proviral clones (2 of
12) may reflect the high concentration of defective proviruses
in the peripheral blood cells (due to recombination and reverse
transcription errors in vivo) described by others or due to
recombination during PCR (17, 35). Our validation of recom-
bination events during long-range PCR to obtain 4.5-kb frag-
ments, however, showed a lower recombination frequency than
FIG. 2. Genomic structures of PBMC-derived full-length clone HIVE4 and the subsequently cloned recombinant viruses containing the 39 half from the different
organs indicated. V3 loop amino acid sequences were determined for all replication-competent clones. All recombinant viruses contain the tissue-specific V3 loop amino
acid sequence representing the major variant in each tissue as determined by Donaldson et al. (22). Ratios in parentheses are the frequencies of the corresponding V3
loop variant in the observed variants (data from reference 22).
VOL. 71, 1997 CHARACTERIZATION OF TISSUE-SPECIFIC HIV-1 CLONES 5143
did the study of Yang et al. (61). The differences might result
from a lower input of targets per PCR and the amplification of
only a 4.5-kb fragment, whereas Yang et al. (61) amplified a
8.2-kb fragment. Thus, a minority of the 39-half proviral clones
described here could result from recombination events during
the PCR. Since we were unable to find any phenotypic differ-
ences in the molecular clones generated, it is likely that any
recombinants resemble the bona fide clones generated. Nev-
ertheless, the sensitivity to detect and obtain long-range PCR
products needs to be improved to reduce the frequency of such
recombinations.
The recently described molecular cloning of full-length HIV
genomes directly from plasma viral RNA (24) is likely to yield
a larger amount of replication-competent clones, although this
has yet to be formally demonstrated. Successful amplification
of proviral 39 halves derived from different tissues made it
possible to construct recombinant proviruses containing the
tat, rev, vpu, and nef genes together with the entire env gene
present in each tissue. The envelope genes in the recombinant
viruses reflect copies of the actual envelope genes present in
these tissues. Since the envelope contains the major determi-
nants for tropism (31, 42, 48, 51, 59, 60), the characterization
of the recombinant viruses constructed as described here might
provide a better understanding of the biological properties of
HIV variants present in different tissues. Full-length molecular
clones of viruses, amplified directly from genomic DNA or
from viral RNA obtained from tissues, should produce viruses
with the actual phenotype present at a specific time point in a
specific tissue. The long-range PCR will result in a remarkable
increase of reference sequences from different viral subtypes
(46) and aid the analysis of the structure of mosaic subtypes
such as A/E recombinations (7). Furthermore, this method
allows the characterization of cell-type-specific virus variants
by using separated cell populations (BDC, monocytes, and
CD41 T lymphocytes) to prepare genomic DNA. The avail-
ability of cell-type-specific clones could provide definitive evi-
dence for tropism switches to BDC (43) and immature thymo-
cytes (56) late in the infection.
Biological characterization of recombinant HIV clones de-
rived from different tissues. Following transfection in 293 cells,
the rescued virus was titrated on uninfected PBMC and the
replication kinetics were assessed after challenging donor
PBMC at a multiplicity of infection of 0.01 (Fig. 3). All recom-
binant clones replicated like slow/low-titer viruses and did not
induce syncytia or infect any of the T-cell lines tested (C8166,
Molt4, and MT-2).
It has been shown that a rapid decline in CD41 T lympho-
cytes often correlates with the development of rapidly repli-
cating SI viruses (15, 52–54). However, in 50% of cases disease
progression also occurs in patients from whom only NSI vi-
ruses can be isolated from the peripheral blood (54). Patient 4
died of AIDS about 5 years after HIV-1 infection without
rescue of SI viruses at the time of death. The molecular clones
HIV-1E4, LN15, S8, B8, and L5 were also tested for their
coreceptor usage and in a single-round infectivity assay showed
positive results only when the chemokine receptors CCR5 and
CCR3 were present (19) (Fig. 4). They were unable to utilize
the chemokine receptor CXCR4, which has been described as
the main coreceptor for SI isolates adapted to replicate in
T-cell lines (25).
NSI virus variants are reportedly able to infect blood MDM,
although with variable kinetics (9, 15). The HIV-1 recombinant
clones described here encode a V3 loop amino acid sequence
resembling the sequence described for primary lymphocyte-
and macrophage-tropic viruses (34) and are able to use the
coreceptors CCR5 and CCR3 (12, 18, 19, 22). However, they
do not infect MDM, suggesting that macrophages might ex-
press these chemokine receptors differently than transfected
cell lines or PBMC. Thus, some HIV-1 isolates or HIV-1
molecular clones are able to use CCR5 or CCR3 only if it is
expressed in a certain way. Our results, however, underline
that macrophage tropism can be correctly assessed only by
performing an infectivity assay using macrophages as target
cells rather than cell lines expressing CD4 and different che-
mokine receptors. The possibility that mutations in the basic
domain of p17gag or the vpr gene by these recombinant clones
resulted in the nonproductive infection of macrophages ob-
served (4, 29, 57) appears unlikely since the recombinant vi-
ruses E4/GUNwt and E4/SF162 readily infected macrophages.
The nef gene is also required for the replication of HIV in
macrophages (36). However, a nef defect would not explain the
restriction for virus entry, as shown by entry PCR.
Patterson et al. (43) reported a higher provirus concentra-
tion in BDC from AIDS patients compared to asymptomatic
HIV-positive patients. To study the susceptibility of BDC to
infection with late HIV-1 variants, we challenged these cells
with each of the recombinant infectious clones we had con-
structed. We did not detect any p24gag in the supernatant of
purified BDC unless they were cocultured one day after infec-
tion with autologous T lymphocytes. Although data for the
susceptibility of dendritic cells are inconsistent (reviewed in
reference 6), it appears that BDC do not support HIV repli-
FIG. 3. Replication kinetics on PBMC after infection at a multiplicity of infection of 0.01. Infections were carried out with 104 TCID50 of each virus on 106
PHA-stimulated PBMC. The cells were washed after 1 day, and virus replication was assessed by measuring HIV p24gag in the culture supernatants.
5144 DITTMAR ET AL. J. VIROL.
cation on their own (5, 44) in vitro, although several studies
have reported a productive infection with macrophage-tropic
viruses (8, 33, 58). Tsunetsugu-Yokota et al. (55) detected a
higher provirus concentration in BDC infected with the SI
strain HIVLAI than in BDC infected with the NSI, macro-
phage-tropic strain HIVBa-L, but they did not detect p24
gag in
culture supernatants. Recent evidence shows that cultured
dendritic cells express the chemokine receptors CXCR4 and
CCR5 and are sensitive to HIV-1 entry (27). We have shown
that several of the recombinant clones derived from different
tissues utilize CCR5 (19). However, it is currently not known
whether virus rescued in the BDC–T-cell coculture is derived
from virus adsorbed on the surface of BDC or from a reacti-
vation of HIV replication in BDC halted during the reverse
transcription stage. Whether cultured dendritic cells express
CCR3 and are susceptible to HIV isolates which can use CCR3
as a coreceptor remains to be shown.
Using genomic DNA from different tissues obtained post-
mortem from one AIDS patient, we found that the long-range
PCR approach allows the construction and characterization of
HIV variants present at a single time point in individual tis-
sues. By avoiding any selection due to isolation of HIV variants
capable of replicating in PHA-stimulated PBMC, these molec-
ular clones reflect genotypes and phenotypes actually present
in these tissues. Characterization of these recombinant clones
revealed no differences in tropism for any primary cell tested.
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